EMA Authorised: Sitagliptin SUN (sitagliptin fumarate) — Sun Pharmaceutical Industries Europe B.V.

View source ↗

Summary

The EMA authorised Sitagliptin SUN (sitagliptin fumarate) for treating Type 2 diabetes mellitus. The marketing authorization holder is Sun Pharmaceutical Indust…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Sitagliptin SUN (sitagliptin fumarate)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Sun Pharmaceutical Industries Europe B.V.. Decision date: 22/10/2025